|
G蛋白偶聯受體
G蛋白偶聯受體（GPCRs）是一類與G蛋白偶聯的細胞表面受體，具有7個跨膜α螺旋結構。G蛋白偶聯受體(GPCRs)能接受許多細胞外信號并傳遞給G蛋白，進而啟動細胞內不同的信號轉導通路。GPCRs介導對環境刺激物、神經遞質、激素、細胞因子和脂質信號分子的多種生理反應，從而在視覺、嗅覺、自主神經系統和行為等生物過程中發揮著重要作用。GPCRs還與眾多疾病相關，是治療許多疾病的重要靶點之一。異常的GPCR功能與病理狀態有關，如神經、免疫和激素紊亂等。
G蛋白偶聯受體信號通路轉導過程
G 蛋白偶聯受體可被多種不同的外界刺激激活。當配體與GPCRs結合時，激活附著在細胞內側端的G蛋白（由α、β、γ三個亞基組成的異源三聚體）。G蛋白上原本結合的GDP被GTP取代，導致α亞基與β-γ亞基復合物解離，并觸發各種不同的信號級聯放大，激活下游信號通路。這些細胞內信號通路包括cAMP/PKA、鈣/NFAT、磷脂酶C（PLC)、蛋白酪氨酸激酶、MAP激酶、PI3K、NO/cGMP、Rho和JAK/STAT等，從而作用于相應的靶分子，進而調控代謝過程及基因表達功能。
G蛋白偶聯受體信號通路圖
產品列表
按靶點分類：
*多巴胺受體
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
靶點 |
IC50 |
Ki |
ED50 |
EC50 |
| B129216 |
Benztropine mesylate |
≥98% |
132-17-2 |
1g,5g |
DAT |
118 nM |
|
|
|
| C131611 |
鹽酸氯丙嗪 |
≥98%(HPLC) |
69-09-0 |
5g,25g,100g |
多巴胺受體 |
6.1 μM |
|
|
|
| 鉀離子通道 |
16 μM |
|
|
|
| C129569 |
鹽酸氯丙嗪 |
分析標準品 |
69-09-0 |
250mg |
多巴胺受體 |
6.1 μM |
|
|
|
| 鉀離子通道 |
16 μM |
|
|
|
| C125175 |
Clemizole |
≥98% |
442-52-4 |
5mg,25mg,100mg |
組胺H1受體 |
|
|
|
|
| B129446 |
Amfebutamone (Bupropion) HCl |
≥98% (HPLC) |
31677-93-7 |
250mg,1g,5g |
多巴胺受體 |
3.4 μM |
|
|
|
| AChR |
6.5 μM |
|
|
|
| T162449 |
三氟拉嗪二鹽酸鹽 |
>98.0%(HPLC)(T) |
440-17-5 |
5g,25g,100g |
多巴胺D2受體 |
1.1 nM |
|
|
|
| D129436 |
Domperidone |
≥98% |
57808-66-9 |
50mg,250mg,1g,5g,25g,100g |
多巴胺D2受體 |
|
|
|
|
| M129977 |
Methyldopa Sesquihydrate |
≥98% |
555-30-6 |
1g,5g,25g |
多巴脫羧酶 |
|
|
21.8 mg/kg |
|
| O126519 |
Olanzapine |
≥99% |
132539-06-1 |
1g,5g |
多巴胺D2受體 |
|
|
|
|
| 5-HT2 |
|
|
|
|
| Q129431 |
Quetiapine Fumarate |
≥98% |
111974-72-2 |
1g,5g |
多巴胺受體 |
|
|
|
|
| E129717 |
Ziprasidone HCl |
≥98% |
122883-93-6 |
250mg,1g |
5-HT |
|
|
|
|
| 多巴胺受體 |
|
|
|
|
| A129432 |
Amisulpride |
≥98% |
71675-85-9 |
50mg,250mg,1g |
多巴胺受體 |
|
|
|
|
| P120141 |
帕利哌酮 |
98% |
144598-75-4 |
10mg,50mg,250mg,1g,5g,25g |
多巴胺受體 |
|
|
|
|
| H113852 |
氟哌啶醇 |
98% |
52-86-8 |
5g,25g |
|
|
|
|
|
| C129441 |
Chlorprothixene |
≥98% |
113-59-7 |
50mg,250mg |
多巴胺D1受體 |
|
18 nM |
|
|
| 多巴胺D2受體 |
|
2.96 nM |
|
|
| 多巴胺D3受體 |
|
4.56 nM |
|
|
| 多巴胺D5受體 |
|
9 nM |
|
|
| 組胺H1受體 |
|
3.75 nM |
|
|
| 5-HT2 |
|
9.4 nM |
|
|
| 5-HT6 |
|
3 nM |
|
|
| 5-HT7 |
|
5.6 nM |
|
|
| P108682 |
吩噻嗪 |
分析標準品 |
92-84-2 |
250mg |
多巴胺-2(D2)受體 |
|
|
|
|
| P108681 |
吩噻嗪 |
98% |
92-84-2 |
100g,500g,5kg |
多巴胺-2(D2)受體 |
|
|
|
|
| D129475 |
Droperidol |
≥98% |
548-73-2 |
50mg,250mg,1g |
|
|
|
|
|
| L129452 |
Levosulpiride |
≥98% |
23672-07-3 |
5g,25g |
多巴胺D2受體 |
|
|
|
|
| T101543 |
延胡索乙素 |
97% |
2934-97-6 |
1g,5g |
|
|
|
|
|
| T101542 |
延胡索乙素 |
分析標準品,>97% |
2934-97-6 |
250mg |
|
|
|
|
|
| P160649 |
Perphenazine |
>97.0% |
58-39-9 |
5g,25g |
多巴胺D1/D2受體 |
|
|
|
|
| H197233 |
6-羥基多巴胺氫溴酸鹽 |
95% |
636-00-0 |
50mg,250mg,1g |
|
|
|
|
|
| C171261 |
Chlorprothixene hydrochloride |
98% |
6469-93-8 |
1g |
|
|
|
|
|
| T162447 |
三氟丙嗪鹽酸鹽 |
>98.0%(HPLC) |
1098-60-8 |
1g,5g |
|
|
|
|
|
| P160772 |
Penfluridol |
>97.0%(HPLC) |
26864-56-2 |
200mg,1g |
多巴胺受體 |
|
1.6 μM |
|
|
| M132784 |
Molindone Hydrochloride |
≥98.0%(HPLC) |
15622-65-8 |
100mg,250mg,1g,5g,25g |
多巴胺D2/D5受體 |
|
|
|
|
| R136626 |
Rotundine |
≥98% |
483-14-7 |
100mg,250mg,500mg |
多巴胺D1受體 |
|
|
|
|
| P160775 |
Sulpiride |
>98.0%(HPLC) |
15676-16-1 |
5g,25g,100g |
多巴胺D2受體 |
|
|
|
|
| T135203 |
丁苯那嗪 |
98% |
58-46-8 |
250mg,1g,5g |
|
|
|
|
|
| A129598 |
Azaperone |
≥99% |
1649-18-9 |
50mg,250mg |
多巴胺受體 |
|
|
|
|
| C184839 |
Chlorpromazine |
95% |
50-53-3 |
1g,5g |
|
|
|
|
|
| M124438 |
甲氧氯普胺 |
98% |
364-62-5 |
5g,25g |
多巴胺受體 |
|
|
|
|
| C171931 |
Cariprazine hydrochloride |
97% |
1083076-69-0 |
1g |
多巴胺D2/D3受體 |
|
|
|
|
| D111048 |
左旋多巴 |
99% |
59-92-7 |
25g,100g,500g |
多巴胺受體 |
|
|
|
|
| D111049 |
左旋多巴 |
分析標準品,>99% |
59-92-7 |
20mg |
多巴胺受體 |
|
|
|
|
| A109736 |
鹽酸金剛烷胺 |
99%（T） |
665-66-7 |
5g,25g,100g,500g |
多巴胺受體 |
|
|
|
|
| P129443 |
Pramipexole 2HCl Monohydrate |
≥98%(HPLC) |
191217-81-9 |
50mg,250mg,1g |
D2S受體 |
|
3.9 nM |
|
|
| D2L受體 |
|
2.2 nM |
|
|
| D3受體 |
|
0.5 nM |
|
|
| D4受體 |
|
5.1 nM |
|
|
| P129434 |
Pramipexole |
≥99% |
104632-26-0 |
10mg,50mg |
D2S受體 |
|
3.9 nM |
|
|
| D2L受體 |
|
2.2 nM |
|
|
| D3受體 |
|
0.5 nM |
|
|
| D4受體 |
|
5.1 nM |
|
|
| D103111 |
鹽酸多巴胺 |
98% |
62-31-7 |
5g,25g,100g,500g,2.5kg |
多巴胺受體 |
|
|
|
|
| P129456 |
Pergolide mesylate |
≥99% |
66104-23-2 |
2.5mg |
|
|
|
|
|
| B178171 |
brexpiprazole |
97% |
913611-97-9 |
1g |
D2L |
|
0.3 nM |
|
|
| 5-HT1A |
|
0.12 nM |
|
|
| 5-HT2A |
|
0.47 nM |
|
|
| α1B受體 |
|
0.17 nM |
|
|
| α2C受體 |
|
0.59 nM |
|
|
| P160771 |
吡貝地爾 |
>98.0%(GC)(T) |
3605-01-4 |
200mg,1g |
|
|
|
|
|
| P129442 |
PD128907 HCl |
≥98% |
112960-16-4 |
5mg,25mg,100mg |
多巴胺D3受體 |
|
|
|
0.64 nM |
| R126364 |
Rotigotine |
≥98% |
99755-59-6 |
10mg,50mg |
多巴胺受體 |
|
|
|
|
| P165634 |
Pramipexole dihydrochloride |
>98% (HPLC) |
104632-25-9 |
10mg,50mg |
D2S受體 |
|
3.9 nM |
|
|
| D2L受體 |
|
2.2 nM |
|
|
| D3受體 |
|
0.5 nM |
|
|
| D4受體 |
|
5.1 nM |
|
|
| M132847 |
MPTP鹽酸鹽 |
≥98% |
23007-85-4 |
25mg,100mg |
|
|
|
|
|
| O101521 |
章胺鹽酸鹽 |
98% |
770-05-8 |
1g,5g |
|
|
|
|
|
*阿片受體
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
靶點 |
IC50 |
Ki |
| R126180 |
Racecadotril |
≥98% |
81110-73-8 |
250mg,1g,5g,25g |
阿片受體 |
4.5 μM |
|
| N129470 |
Naloxone HCl |
≥99% |
357-08-4 |
50mg,250mg,1g |
|
|
|
| J125889 |
JTC-801 |
≥99% |
244218-51-7 |
5mg,10mg,50mg |
ORL1 |
94 nM |
|
| N129461 |
Naltrexone HCl |
≥99% |
16676-29-2 |
50mg,250mg,1g |
阿片受體 |
8 nM |
|
| A124975 |
Alvimopan |
≥98% |
156053-89-3 |
25mg,100mg |
μ阿片受體 |
|
0.77 nM |
| δ阿片受體 |
|
4.4 nM |
| κ阿片受體 |
|
40 nM |
| L129465 |
Loperamide HCl |
≥98% |
34552-83-5 |
5g,25g |
μ阿片受體 |
|
3.3 nM |
| δ阿片受體 |
|
48 nM |
| A127848 |
ADL5859 HCl |
≥98% |
850173-95-4 |
1mg,5mg,10mg,50mg |
δ阿片受體 |
|
0.8 nM |
| M109803 |
苦參堿 |
98% |
519-02-8 |
100mg,1g,5g,25g |
κ阿片受體 |
|
|
| M109802 |
苦參堿 |
分析標準品,≥98% |
519-02-8 |
20mg |
κ阿片受體 |
|
|
| T129468 |
Trimebutine |
≥98% |
39133-31-8 |
250mg,5g,25g,100g |
μ阿片受體 |
|
|
| δ阿片受體 |
|
|
| κ阿片受體 |
|
|
| M129400 |
Meptazinol HCl |
≥99% |
59263-76-2 |
10mg,50mg,250mg |
阿片受體 |
|
|
*大麻素受體
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
靶點 |
IC50 |
Ki |
EC50 |
| O135157 |
橄欖醇 |
95% |
500-66-3 |
1g,5g |
|
|
|
|
| R125003 |
Rimonabant |
≥98% |
168273-06-1 |
10mg,50mg,500mg |
hCB1 |
13.6 nM |
|
|
| A129844 |
AM251 |
≥98% |
183232-66-8 |
5mg,25mg,100mg |
CB1 |
700 nM |
|
|
| C129834 |
CP-945598 HCl |
≥98% |
686347-12-6 |
10mg,50mg |
CB1 |
|
0.7 nM |
|
| A129838 |
AM1241 |
≥98% |
444912-48-5 |
5mg,10mg,25mg,50mg |
CB2 |
3.4 nM |
|
|
| B126713 |
BML-190 |
≥99% |
2854-32-2 |
10mg,50mg |
CB2 |
435 nM |
|
|
| G129840 |
GW842166X |
≥98% |
666260-75-9 |
5mg,25mg,100mg |
CB2 |
|
|
63 nM |
| O129837 |
Org 27569 |
≥98% |
868273-06-7 |
10mg,50mg |
CB1 |
|
|
|
*內皮素受體
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
靶點 |
IC50 |
| Z125040 |
Zibotentan (ZD4054) |
≥98% |
186497-07-4 |
5mg,25mg,100mg |
ET-A |
21 nM |
| B129849 |
Bosentan Hydrate |
≥99% |
157212-55-0 |
50mg,250mg,1g,5g |
ET-A |
4.7 nM |
| ET-B |
95 nM |
| M125524 |
Macitentan |
≥97% |
441798-33-0 |
5mg,25mg,100mg,1g |
ET-A |
0.5 nM |
| ET-B |
391 nM |
| A126631 |
Ambrisentan |
≥99% |
177036-94-1 |
5mg,10mg,20mg,100mg,250mg,1g |
ET-A |
18 nM |
*S1P受體
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
細胞 |
靶點 |
IC50 |
Ki |
EC50 |
| S129855 |
SKI II |
≥98% |
312636-16-1 |
5mg,25mg,100mg |
|
SphK |
0.5 μM |
|
|
| P125702 |
PF-543 |
- |
1415562-82-1 |
5mg,10mg,50mg |
|
SphK1 |
|
3.6 nM |
|
| A127517 |
ABC294640 |
≥99% |
915385-81-8 |
5mg,10mg,50mg |
|
SphK2 |
60 μM |
|
|
| F126599 |
Fingolimod HCl |
≥98% |
162359-56-0 |
100mg,200mg,250mg,1g |
K562 、NK細胞 |
S1P |
0.33 nM |
|
|
| P177659 |
Ponesimod |
97% |
854107-55-4 |
100mg |
|
S1P1 |
|
|
5.7 nM |
*Hedgehog/Smoothened
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
細胞 |
靶點 |
IC50 |
Ki |
Kd |
| V127477 |
Vismodegib (GDC-0449) |
98% |
879085-55-9 |
10mg,50mg,100mg,250mg,500mg,1g |
無細胞 |
hedgehog |
3 nM |
|
|
| L125247 |
LY2940680 |
≥99% |
1258861-20-9 |
5mg,10mg,50mg |
|
Smo |
|
|
|
| J169510 |
JK184 |
98% (HPLC) |
315703-52-7 |
5mg,25mg |
哺乳動物細胞 |
Gli |
30 nM |
|
|
| J135916 |
Jervine |
>97.0%(HPLC) |
469-59-0 |
10mg,25mg,50mg,100mg,250mg |
|
Hedgehog |
500-700 nM |
|
|
| C125994 |
Cyclopamine |
≥99% |
4449-51-8 |
5mg,10mg,50mg |
TM3Hh12細胞 |
Smo |
46 nM |
|
|
| L127562 |
NVP-LDE225 |
≥99% |
956697-53-3 |
10mg,50mg,100mg |
無細胞 |
Smo (小鼠) |
1.3 nM |
|
|
| 無細胞 |
Smo (人) |
2.5 nM |
|
|
| P126554 |
PF-5274857 |
≥99% |
1373615-35-0 |
5mg,10mg,50mg |
|
Smo |
5.8 nM |
4.6 nM |
|
| S129830 |
SANT-1 |
≥98% |
304909-07-7 |
5mg,25mg,100mg |
|
Smo |
|
|
1.2 nM |
| B126389 |
BMS-833923 |
≥99% |
1059734-66-5 |
10mg,50mg |
|
Smo |
|
|
|
| P126030 |
Purmorphamine |
≥98% |
483367-10-8 |
5mg,25mg,100mg |
HEK293T細胞 |
Smo |
~1.5 μM |
|
|
*SGLT
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
細胞 |
靶點 |
IC50 |
EC50 |
| D126800 |
Dapagliflozin |
≥99% |
461432-26-8 |
10mg,50mg,250mg,1g |
CHO細胞 |
hSGLT2 |
|
1.1 nM |
| C126191 |
Canagliflozin |
≥98% |
842133-18-0 |
10mg,50mg,250mg,1g |
無細胞 |
SGLT2 |
2.2 nM |
|
| E127439 |
Empagliflozin (BI 10773) |
≥99% |
864070-44-0 |
5mg,25mg,100mg,500mg,1g |
|
SGLT2 |
3.1 nM |
|
| L127607 |
LX-4211 |
≥98% |
1018899-04-1 |
5mg,10mg,50mg |
|
SGLT1 |
36 nM |
|
| SGLT2 |
1.8 nM |
|
| I177384 |
Ipragliflozin |
97% |
761423-87-4 |
10mg,25mg,50mg,100mg,1g |
|
hSGLT2 |
7.4 nM |
|
| P127748 |
根皮素 |
≥98% |
60-82-2 |
250mg,1g,5g |
|
SGLT1 |
|
|
| SGLT2 |
|
|
| P139206 |
根皮苷 |
≥98% |
60-81-1 |
250mg,1g |
|
|
|
|
| P127306 |
PF-04971729 |
≥98% |
1210344-57-2 |
5mg,10mg,50mg |
|
hSGLT2 |
0.877 nM |
|
*SGLT
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
細胞 |
靶點 |
Ki |
| K126742 |
Ki16425 |
≥98% |
355025-24-0 |
2mg,5mg,25mg |
RH7777細胞系 |
LPA1 |
0.34 μM |
| LPA2 |
6.5 μM |
| LPA3 |
0.93 μM |
| K129869 |
Ki16198 |
≥99% |
355025-13-7 |
5mg,10mg,50mg |
|
LPA1 |
0.34 μM |
| LPA3 |
0.93 μM |
*OX受體
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
| A129661 |
Alverine Citrate |
≥99% |
5560-59-8 |
5g,25g |
| S117970 |
五味子酯甲 |
分析標準品,>98% |
58546-56-8 |
20mg,100mg |
*CGRP受體
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
靶點 |
Ki |
| B125641 |
BMS-927711 |
- |
1289023-67-1 |
10mg,25mg,100mg |
CGRP |
0.027 nM |
*MT受體
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
靶點 |
Ki |
pKi |
| R125051 |
Ramelteon |
≥99% |
196597-26-9 |
10mg,50mg,100mg |
MT1 |
14 pM |
|
| MT2 |
112 pM |
|
| 小雞前腦MT |
23.1 pM |
|
| M118674 |
褪黑素 |
98% |
73-31-4 |
250mg,1g,5g,25g,100g |
MT |
|
|
| T176929 |
Tasimelteon |
97% |
609799-22-6 |
100mg |
MT1 |
|
9.45 |
| MT2 |
|
9.8 |
*PAFR
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
靶點 |
IC50 |
| G101969 |
銀杏內酯B |
分析標準品,≥99% |
15291-77-7 |
10mg,50mg |
PAFR |
3.6 μM |
*PKA
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
細胞 |
靶點 |
IC50 |
Ki |
| A126845 |
A-674563 |
≥98% |
552325-73-2 |
5mg,25mg,100mg |
|
PKA |
|
16 nM |
| Akt |
|
11 nM |
| H129712 |
H 89 2HCl |
≥99% |
130964-39-5 |
10mg,50mg |
無細胞 |
PKA |
|
48 nM |
| D155111 |
Daphnetin |
>90.0%(HPLC) |
486-35-1 |
50mg,250mg,1g |
|
EGFR |
7.67 μM |
|
| PKA |
9.33 μM |
|
| PKC |
25.01 μM |
|
| D124575 |
N6,2′-O-二丁?；佘?′,5′-環磷酸 鈉鹽 |
≥97% (HPLC) |
16980-89-5 |
25mg,100mg,250mg,1g |
|
PKA |
|
|
*腺苷受體
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
靶點 |
IC50 |
Ki |
| L125077 |
5-Iodotubercidin |
≥98% |
24386-93-4 |
5mg,25mg |
腺苷激酶 |
26 nM |
|
| I125338 |
Istradefylline |
≥99% |
155270-99-8 |
5mg,25mg,100mg |
A2AR |
|
2.2 nM |
| H157070 |
7-(2-羥丙基)茶堿 |
>98.0%(HPLC)(N) |
603-00-9 |
1g,5g,25g |
A1腺苷 |
|
|
| S167655 |
SCH 58261 |
98% (HPLC) |
160098-96-4 |
5mg,10mg,25mg,50mg,100mg |
bovine A2a |
|
2.0 nM |
| rat A2a |
|
2.3 nM |
| R126916 |
Reversine |
≥97%(HPLC) |
656820-32-5 |
5mg,10mg,50mg,100mg,250mg |
人A3腺苷受體 |
0.66 μM |
| aurora A |
12 nM |
|
| aurora B |
13 nM |
|
| aurora C |
20 nM |
|
| T111224 |
茶堿乙酸 |
98% |
652-37-9 |
25g,100g,500g |
|
|
|
| A108807 |
腺嘌呤核苷 |
分析標準品 |
58-61-7 |
20mg |
|
|
|
| A108806 |
腺嘌呤核苷 |
用于細胞培養,>99.5%(HPLC) |
58-61-7 |
5g,25g |
|
|
|
| A108808 |
腺嘌呤核苷 |
超純級,99.5% |
58-61-7 |
1g,5g,25g,100g |
|
|
|
| A108809 |
腺嘌呤核苷 |
BC,99% |
58-61-7 |
25g,100g |
|
|
|
*CaSR
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
靶點 |
IC50 |
EC50 |
| C129866 |
Cinacalcet HCl |
≥99% |
364782-34-3 |
10mg,50mg,250mg,1g,5g |
CaSR |
|
2.8 μM |
| N125903 |
NPS-2143 |
≥98% |
284035-33-2 |
5mg,25mg,100mg |
Ca(2+)受體 |
43 nM |
|
*CXCR
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
細胞 |
靶點 |
IC50 |
| T103998 |
單寧酸 |
AR |
1401-55-4 |
10g,25g,100g,250g,500g |
|
CXCL12 |
|
| CXCR4 |
|
| R126706 |
Reparixin |
≥98% |
266359-83-5 |
5mg,25mg,100mg |
|
CXCR1 |
|
| CXCR2 |
|
| CXCL8 |
|
| P129846 |
Plerixafor 8HCl (AMD3100 8HCl) |
≥99% |
155148-31-5 |
5mg,10mg,50mg |
|
CXCR4 |
44 nM |
| CXCL12 |
5.7 nM |
| P128026 |
Plerixafor |
≥98% |
110078-46-1 |
10mg,50mg,250mg |
無細胞 |
CXCR4 |
44 nM |
| CXCL12 |
5.7 nM |
| D178502 |
danirixin |
97% |
954126-98-8 |
100mg |
|
CXCL8 |
12.5 nM |
*血管升壓素受體
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
靶點 |
IC50 |
| C129921 |
Conivaptan HCl |
≥99% |
168626-94-6 |
10mg,50mg,250mg |
加壓素受體1 |
|
| 加壓素受體2 |
|
| T129870 |
Tolvaptan |
≥98% |
150683-30-0 |
10mg,50mg,250mg,1g |
加壓素受體2 |
1.28μM |
| M129872 |
Mozavaptan |
≥99% |
137975-06-5 |
10mg,50mg |
加壓素受體1 |
1.2 μM |
| 加壓素受體2 |
14 nM |
*cAMP
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
靶點 |
IC50 |
EC50 |
| B101323 |
硫雙二氯酚 |
97% |
97-18-7 |
25g,100g,500g |
sAC |
4.0 μM |
|
| F127328 |
Forskolin |
≥98% |
66575-29-9 |
10mg,50mg,100mg,500mg,1g |
AC |
|
|
| P118976 |
PACAP(6-38), human, ovine, rat |
98% |
137061-48-4 |
1mg,5mg,25mg |
PAC1 |
|
1.1 nM |
| PAC1s |
|
1.7 nM |
| PAC1vs |
|
121 nM |
*TAAR
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
靶點 |
Ki |
| T101154 |
色胺 |
98% |
61-54-1 |
5g,25g,100g,500g |
hTAAR1 |
1.08 μM |
| T105543 |
酪胺 |
98% |
51-67-2 |
1g,5g,25g,100g,500g |
hTAAR1 |
34 nM |
*前列腺素受體
| 項目號 |
產品名稱 |
規格 |
CAS |
包裝 |
| B129831 |
Bimatoprost |
≥99% |
155206-00-1 |
10mg,50mg,100mg,500mg |
| P129960 |
Prostaglandin E1 |
≥98%(HPLC) |
745-65-3 |
5mg,25mg,100mg |
| D133402 |
Dinoprostone |
98% |
363-24-6 |
1mg,10mg,25mg |
| D136300 |
Dinoprost |
≥99% |
38562-01-5 |
1mg,5mg,25mg,100mg |
| E129511 |
Ethamsylate |
≥98% |
2624-44-4 |
1g,5g,25g,100g |
|
|